Wall Street Zen Downgrades Maze Therapeutics (NASDAQ:MAZE) to Sell

Maze Therapeutics (NASDAQ:MAZE) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Other analysts have also issued research reports about the company. Wedbush upped their price objective on Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Lifesci Capital raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. BTIG Research increased their price target on shares of Maze Therapeutics from $37.00 to $46.00 and gave the company a “buy” rating in a report on Friday, January 16th. Raymond James Financial initiated coverage on Maze Therapeutics in a report on Thursday, November 13th. They set an “outperform” rating and a $48.00 price objective for the company. Finally, Wells Fargo & Company assumed coverage on Maze Therapeutics in a research report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $44.50.

Maze Therapeutics Trading Up 2.5%

NASDAQ MAZE opened at $45.03 on Friday. The firm has a market capitalization of $2.17 billion and a P/E ratio of -2.15. The firm’s fifty day moving average price is $41.74 and its two-hundred day moving average price is $30.19. Maze Therapeutics has a 1 year low of $6.71 and a 1 year high of $49.25.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.08.

Insider Activity

In related news, CMO Harold Bernstein sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $46.02, for a total value of $690,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Amy Bachrodt sold 5,000 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $46.04, for a total value of $230,200.00. Following the transaction, the senior vice president owned 12,965 shares in the company, valued at approximately $596,908.60. This trade represents a 27.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 200,000 shares of company stock worth $8,254,792.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. CWM LLC acquired a new stake in Maze Therapeutics during the second quarter worth about $28,000. GF Fund Management CO. LTD. bought a new stake in shares of Maze Therapeutics during the 4th quarter worth approximately $39,000. Ameritas Investment Partners Inc. boosted its position in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after acquiring an additional 738 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after acquiring an additional 1,725 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in Maze Therapeutics in the third quarter valued at approximately $52,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.